Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Bristol-Myers Squibb Company ( BMY) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 1.5%. By the end of trading, Bristol-Myers Squibb Company fell 50 cents (-1.5%) to $32.12 on light volume. Throughout the day, seven million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.4 million shares. The stock ranged in price between $32.12-$32.61 after having opened the day at $32.59 as compared to the previous trading day's close of $32.62. Other companies within the Health Care sector that declined today were: Catalyst Pharmaceutical Partners ( CPRX), down 65.5%, Biocryst Pharmaceuticals ( BCRX), down 40.4%, Progenics Pharmaceuticals ( PGNX), down 26.3%, and Pluristem Therapeutic ( PSTI), down 22.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Bristol-Myers Squibb Company, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $54.92 billion and is part of the drugs industry. The company has a P/E ratio of 30, above the S&P 500 P/E ratio of 17.7. Shares are down 7.4% year to date as of the close of trading on Wednesday. Currently there are eight analysts that rate Bristol-Myers Squibb Company a buy, one analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact